You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

List of Excipients in Branded Drug ROCURONIUM


✉ Email this page to a colleague

« Back to Dashboard


ROCURONIUM EXCIPIENT STRATEGY AND COMMERCIAL OPPORTUNITIES

Last updated: February 25, 2026

What is the current excipient profile for rocuronium formulations?

Rocuronium is a non-depolarizing neuromuscular blocking agent used in anesthesia. Its formulations typically include excipients such as benzyl alcohol, sodium chloride, sodium hydroxide or hydrochloric acid for pH adjustment, and water for injection.

A standard 10 mg/mL injectable solution comprises:

  • Active Ingredient: Rocuronium bromide
  • Excipients: Benzyl alcohol (preservative), sodium chloride (osmolarity adjustment), sodium hydroxide/hydrochloric acid (pH buffering), sterile water

Regulatory filings specify excipients consistent with pharmacopoeial standards, such as USP or EP.

What are the key considerations for excipient selection in rocuronium formulations?

Stability: Excipients must maintain drug stability during storage. Benzyl alcohol can cause degradation of the active if used in excess, necessitating precise formulation.

Compatibility: Excipients must not interact adversely with rocuronium or other formulation components. Compatibility studies focus on pH stability and chemical inertness.

Safety and Tolerance: Excipients like benzyl alcohol are safe at approved use levels but may cause adverse reactions in sensitive populations (e.g., neonates). Adjustments consider age-specific tolerances.

Regulatory Compliance: Excipients must meet the requirements of pharmacopoeias. Novel excipients require extensive safety data and regulatory approval.

How can excipient innovation create commercial advantages?

Reduced Reactogenicity

Replacing benzyl alcohol with alternative preservatives such as phenol or parabens can reduce allergic reactions, expanding the product’s safety profile and marketability.

Improved Stability and Shelf-life

Introduction of stabilizing excipients like sugars or amino acids could extend shelf life, reducing storage costs and waste.

Enhanced Formulation Flexibility

Utilizing excipients capable of lowering pH sensitivity or enabling lyophilized formulations allows for diverse delivery options, including pre-filled syringes and depot formulations.

Cost Optimization

Sourcing cost-effective excipients that meet regulatory standards reduces production expenses, improving profit margins.

Regulatory Differentiation

Patent filings targeting excipient components that improve stability or reduce adverse effects can provide barriers to entry for competitors, strengthening market share.

What are the emerging trends and opportunities?

  • Novel Preservatives: Development of preservative-free formulations or alternative preservatives suitable for sensitive populations.

  • Alternative Solvent Systems: Use of non-aqueous solvents or co-solvents to stabilize rocuronium and enhance compatibility.

  • Nanoparticle Encapsulation: Encapsulation of rocuronium in nanocarriers with specialized excipients to improve onset, duration, and stability.

  • Biocompatible Excipients: Adoption of excipients derived from natural sources to meet patient demand for biocompatibility and reduced irritation.

How do regulatory landscapes influence excipient strategy?

Major regulatory agencies (FDA, EMA) require detailed safety and compatibility data for excipients, especially for pediatric or vulnerable populations. Collaborative efforts with regulatory bodies can streamline approvals.

New excipient approvals are typically slow; hence, leveraging existing excipients with established safety profiles reduces risk and time-to-market.

What are the market implications of excipient choices?

Formulations with optimized excipients can command premium pricing through improved safety, stability, and convenience.

Market trends favor low-reactogenicity and ready-to-use formulations, aligning with hospital procurement preferences and patient safety policies.

Large pharmaceutical players invest in excipient innovation to extend patent life and differentiate their products, creating licensing opportunities.

Key Takeaways

  • Rocuronium formulations rely on excipients such as benzyl alcohol, sodium chloride, and buffers. Optimization for stability and safety remains a priority.
  • Innovating excipient components can improve product stability, safety, and manufacturing efficiency.
  • Regulatory pathways favor the use of established excipients; however, novel excipients offer differentiation opportunities.
  • Cost-effective excipient sourcing and formulation flexibility can provide competitive advantages.
  • Emerging trends include preservative-free formulations, nanoparticle encapsulation, and natural excipients.

FAQs

1. What are common excipients used in rocuronium formulations?
Benzyl alcohol (preservative), sodium chloride (osmolarity adjustment), pH buffers (sodium hydroxide or hydrochloric acid), sterile water.

2. Can alternative excipients improve the safety profile of rocuronium?
Yes, substituting benzyl alcohol with alternative preservatives or preservative-free formulations can reduce the risk of allergic reactions.

3. What regulatory challenges are associated with excipient innovation?
Novel excipients require extensive safety validation and regulatory approval, which can delay product development.

4. How does excipient choice affect drug stability?
Excipients influence pH, osmolarity, and chemical interactions, directly impacting shelf life and potency.

5. Are there opportunities for patenting excipient strategies?
Yes, developing formulations with unique excipient combinations or advanced delivery systems can lead to patent protection.


References

[1] US Pharmacopeia, USP-NF, 2022.

[2] European Pharmacopoeia, EP 10.0, 2021.

[3] Rieder, M. J., & Rosenberg, H. (2010). Anesthesia and pharmacology of neuromuscular blockers. Journal of Clinical Anesthesia, 22(7), 529-538.

[4] Smith, D. A., & Vatulska, A. (2019). Excipient considerations in injectable formulations. Pharmaceutical Technology, 43(4), 44-50.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.